New Stem Cell R&D Lab by Cell BioEngines

Cell BioEngines has signed a new lab lease at the Center for Engineering and Precision Medicine (CEPM), a collaborative initiative between Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai. The lease will begin on May 1st, 2025.

Cell BioEngines is a clinical-stage biotechnology company developing a universal ‘plug-and-play’ allogeneic (donor-derived) stem cell therapy platform along with a portfolio of off-the-shelf cell therapies designed to treat hematologic (blood-related) and solid tumor malignancies.

The company reports that the new laboratory space at CEPM will facilitate expanded internal research and development activities, enabling access to advanced technology and resources provided by the CEPM facilities. This move also builds upon the existing relationship between Cell BioEngines and Mount Sinai, and underscores the company’s ongoing presence in the New York City region.

“The decision to establish our presence in CEPM, is a strategic move for Cell BioEngines. It gives us access to a collaborative, complementary group of researchers and core facilities to support the further development of our platform technologies and therapeutic pipeline, opening opportunities for new translational programs in both immune-engineering and regenerative medicine. Our decision is also very timely as the city’s strategy to emerge from the pandemic stronger has sparked remarkable innovation in New York’s biotech and life sciences sector, particularly through advancements in real estate and workforce development. This is a promising sign of growth when considering our expansion efforts. And not to forget, New York is an ideal location for meeting potential partners, accessing a diverse talent pool, and tapping into a broader market—all of which are crucial for the growth of an early-stage company like ours,” said Dr. Ajay Vishwakarma, CEO and Founder of Cell BioEngines.

“CEPM represents a unique state-of-the-art public-private ecosystem designed to support growth and innovation by using engineering and advanced computing to rapidly move forward biomedical and life sciences startups and early-stage companies like Cell BioEngines that are creating the future of medicine. Cell BioEngines is an excellent fit with our research and development foci in regenerative and reparative medicine, immuno-engineering and neuromodulation, and we welcome them into our space. We are looking forward to supporting their needs through collaboration, availability of high-end equipment for advanced manufacturing and quality control, education and workforce development programs,” said Deepak Vashishth, Ph.D., Co-Director of CEPM.

Similar stories

Cellares and GenomeFrontier Therapeutics Partnering on Automated Virus-Free CAR-T Program for Phase 1Sep 17, 2026Vyriad Begins Mayo Clinic CAR-T Phase 1 for Multiple MyelomaSep 14, 2026FDA Clears Colorado University Anschutz’ CAR T-Cell Trial for Colorectal CancerSep 11, 2026Cell Therapies to Manufacture CAR-T Therapy for Phase 1/2b Solid Tumor Trial in AustraliaJul 12, 2026

Editor’s Picks

Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND SoonOct 20, 2026Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis TrialOct 18, 2026Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic AcidOct 18, 2026Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell TherapyOct 4, 2026